Login to Your Account



Other news to note


Friday, December 13, 2013
Ico Therapeutics Inc., of Vancouver, British Columbia, said its oral amphotericin B is moving into in vitro testing with study partners in Montreal to examine the role of the formulation in targeting latent HIV reservoirs.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription